Brandon Faubert to Carcinoma, Non-Small-Cell Lung
This is a "connection" page, showing publications Brandon Faubert has written about Carcinoma, Non-Small-Cell Lung.
Connection Strength
1.023
-
Lactate Metabolism in Human Lung Tumors. Cell. 2017 Oct 05; 171(2):358-371.e9.
Score: 0.304
-
High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non-Small Cell Lung Cancer in Patients. Cancer Discov. 2025 Apr 02; 15(4):702-716.
Score: 0.128
-
Concurrent loss of LKB1 and KEAP1 enhances SHMT-mediated antioxidant defence in KRAS-mutant lung cancer. Nat Metab. 2024 Jul; 6(7):1310-1328.
Score: 0.121
-
The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer. Nat Metab. 2020 12; 2(12):1401-1412.
Score: 0.095
-
Concentration-dependent Early Antivascular and Antitumor Effects of Itraconazole in Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 11 15; 26(22):6017-6027.
Score: 0.093
-
Does Tumor FDG-PET Avidity Represent Enhanced Glycolytic Metabolism in Non-Small Cell Lung Cancer? Ann Thorac Surg. 2020 04; 109(4):1019-1025.
Score: 0.088
-
Metabolic Diversity in Human Non-Small Cell Lung Cancer Cells. Mol Cell. 2019 12 05; 76(5):838-851.e5.
Score: 0.087
-
Metabolic Heterogeneity in Human Lung Tumors. Cell. 2016 Feb 11; 164(4):681-94.
Score: 0.068
-
Reactive metabolite production is a targetable liability of glycolytic metabolism in lung cancer. Nat Commun. 2019 12 06; 10(1):5604.
Score: 0.022
-
CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells. Nature. 2017 06 01; 546(7656):168-172.
Score: 0.019